Anzeige
Mehr »
Mittwoch, 22.07.2026 - Börsentäglich über 12.000 News
Aktie im Fokus: Gelingt jetzt der Turnaround?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DW24 | ISIN: SE0008091664 | Ticker-Symbol: 5LU
Frankfurt
22.07.26 | 08:08
0,006 Euro
+16,00 % +0,001
1-Jahres-Chart
SIMRIS GROUP AB Chart 1 Jahr
5-Tage-Chart
SIMRIS GROUP AB 5-Tage-Chart

Aktuelle News zur SIMRIS GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.07.Simris Group AB: Simris Group Ab Appoints Adc Expert Professor Andreas Pahl As Chief Executive Officer Of Its Subsidiary Simris Biologics Gmbh244Simris Group AB (SIMRIS B) today announced the appointment of Professor Andreas Pahl as Chief Executive Officer of Simris Biologics GmbH, its wholly owned subsidiary based in Berlin, Germany. Professor...
► Artikel lesen
24.06.Simris Group AB: Bulletin from Simris Group AB's annual general meeting171Simris Group AB (publ), reg. no. 556841-9187 (the "Company"), held its annual general meeting on 24 June 2026. Below follows a summary of the resolutions that were passed at the general meeting Income...
► Artikel lesen
13.05.Simris Group AB: Simris Group Interim Report January-march 2026216QUARTER 1, JANUARY - MARCH 2026Net revenue increased by 167% to SEK 424k (159k).EBITDA improved by 41% to SEK -2 183k (-3 724k).EBIT/Operating result improved by 23% to SEK -5 626k (-7 288k).KEY EVENTS...
► Artikel lesen
12.05.Simris Group AB: Simris Group Advances Asset Divestment Process with Two Prospective Buyers360Simris Group AB (Simris or the Company) today announces progress in its strategic divestment process for its microalgae production facility in Hammenhög, Sweden. Simris has entered into a Memorandum...
► Artikel lesen
11.03.Simris Group AB: Simis provides an update on the divestment of its assets in Hammenhög, Sweden201Simris Group AB ("Simris" or the "Company") announces that discussions with Immunrise Biocontrol France SAS ("Immunrise") continue, on a non-exclusive basis, beyond the deadline of March 1, 2026 and...
► Artikel lesen
28.02.Simris Group AB: Simris Group Year-end Report January-december 2025490QUARTER 4, JULY - DECEMBER 2025Net revenue decreased by 71% to SEK 285k (971k).EBITDA declined by 63% to SEK -5 196k (-3 180k).EBIT/Operating result improved by 9% to SEK -8 429 (-9 241k).YEAR-END PERIOD...
► Artikel lesen
SIMRIS GROUP Aktie jetzt für 0€ handeln
19.01.Simris Group AB: Bulletin from Simris Group AB's extraordinary general meeting334Simris Group AB (publ), reg. no. 556841-9187 (the "Company"), held an extraordinary general meeting on 19 January 2026. Below follows a summary of the resolutions that were passed at the general meeting. Election...
► Artikel lesen
12.11.25Simris Group AB receives observation status258Today, November 12, 2025, Simris Group AB (the "Company") disclosed its interim report for the third quarter of 2025 with information on the Company's financial situation. The rules of Nasdaq...
► Artikel lesen
12.11.25Simris Group AB: Simris Group Interim Report January-september 2025286QUARTER 3, JULY - SEPTEMBER 2025Net revenue decreased by 37% to SEK 484k (766k).EBITDA declined by 22% to SEK -3 639k (-2 971k).EBIT/Operating result declined by 8% to SEK -7 152k (-6 614k).INTERIM...
► Artikel lesen
10.11.25Simris Group AB: Simris Group announces leadership transition - Daniel Kubitza appointed interim CEO335The Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective immediately. Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and...
► Artikel lesen
05.11.25Simris Group AB: Simris Group AB Announces Positive Results from Ongoing Antibody-Drug Conjugate (ADC) Study with Nuvisan274Simris Group AB's wholly owned subsidiary, Simris Biologics GmbH, today announced important progress in its ongoing preclinical study with Nuvisan, a leading European contract research and development...
► Artikel lesen
06.10.25Simris Group AB: Update Regarding In-Vitro Evaluation of Novel Advance Microcystin Payloads346Simris Group AB wholly owned subsidiary, Simris Biologics GmbH, today announced short technical delays in a previously announced study contracted with Nuvisan, a leading European contract research and...
► Artikel lesen
12.09.25Simris Group AB: Simris Biologics awarded €200K in non-dilutive funding for R&D programme to further develop microcystin payloads for Antibody Drug Conjugates (ADCs)1.034Simris Group AB, a pioneer in the development of novel, next-generation Antibody Drug Conjugate (ADC) payloads based on Microcystin (MC) toxin variants, announces that funding has been approved for...
► Artikel lesen
13.08.25Simris Group AB: Simris Group Interim Report January-june 2025323QUARTER 2, APRIL - JUNE 2025Net revenue increased by 8% to SEK 687k (634k).EBITDA improved by 51% to SEK -2 980k (-6 117k).EBIT/Operating result improved by 32% to SEK -6 693k (-9 822k).INTERIM PERIOD...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1